*Sponsored by Sica Media
Hey Folks, Jeff here again!
On Friday, I went live to explain that my viewers weren’t imagining it – this is a difficult time to trade.
Earlier in the week, I sent this email out to everyone since I was getting so many questions about betting against stocks right now.
I know the tendency traders have to jump on the bandwagon when things are going south for the markets. They want to either sell everything near the bottom, or they want to get aggressive and start to bet against stocks when things look ugly.
I think both of these are the wrong moves to make.
At times like these, a single piece of news can cause many people to wind up on the wrong side of their trades, resulting in big correction days like we saw Friday.
But that’s no reason to stay in the dugout. Instead, I argued that now’s the time to wait for what I call “fat pitches” to come along — high-confidence moves based on solid technicals.
Well, folks, today I see one coming right over the plate.
Let’s dig in…
I first wrote to you about Swiss-based NLS Pharmaceutics (NASDAQ: NLSP) in late-August.
As I wrote at the time, “We don’t often see setups like these so it is imperative to take full advantage when they do come around.”
If you paid attention to that, you then witnessed NLSP make a double-digit move higher over the next week, before consolidating one more time, and ultimately making a clear breakout over 20% higher.
Well folks, I’ve stayed tuned to the NLSP story since then and right now my favorite indicators are signaling that we may be on the cusp of another major breakout.
Check this out:
That’s the analysis of an advanced, computer-generated algorithm that considers over a dozen different momentum indicators to determine the most likely trend going forward.
This “go/no go” algorithm is the single-best computer-generated indicator I look to for confirmation on when to enter a trade. When I layer it on top of my own indicators and analysis, it gives me a very high-level of confidence in my personal trading..
As you can see, I’ve highlighted several very quick and sizable recent gains…
A 66% move in 4 days… a 40% move in a single day… a 22% move in 2 days… and a 42% move in 5 days…
…And this is all just since June!
In three of those reversals, you can see multiple, conflicting go/no-go markers along the trendline just before the chart legged up. These mixed signals are a classic indicator I’ve seen play out countless times before reversals.
And that brings me to what I am seeing today. Those conflicting go/no-go markers suggest we could be very close to an inflection point, just like when I first alerted you to NLSP on August 22, before it made a 42% move higher.
Looking at the chart of the last week, I’m not surprised those markers are flashing:
As you can see, by the end of last week, NLSP was trading flat overall, but had tested new highs that were at least 10% moves up throughout the week.
Yesterday morning kicked off with yet another 10% spike before settling in at recent support above $.70.
This is often what the valley of a reversal will look like. Rarely will a stock rocket straight up at the end of a weeks-long drawdown. Instead, it will test the breakout repeatedly before making its ultimate swing.
This is a great indication that an upside move is coming, and that it could be dramatic.
For further confirmation, Yahoo! Finance is lighting up “bullish” on the slow stochastic oscillator, which you can read about in detail here.
In brief, the slow stochastic helps us distinguish signal from noise by comparing the latest closing price to the highs and lows over the last 14 periods. This popular indicator is also giving a green light.
Checking the news cycle, we just received this report from Fintel last week:
- The average one-year price target for NLS Pharmaceutics (NLSP) has been revised to $9.94 / share. This is an increase of 24.47% from the prior estimate of 7.99 dated August 31, 2023.
- The price target is an average of many targets provided by analysts. The latest targets range from a low of 6.06 to a high of 14.18 / share. The average price target represents an increase of 1,286.84% from the latest reported closing price of 0.72 / share.
That’s right, the average price target represents a 10-bagger opportunity 💰.
Of course, since NLSP is a clinical-stage pharmaceutical company, a lot of that depends on the success of the company’s drug trials…
In case you missed my earlier reports, NLSP is on the cusp of its Phase 3 trial for its leading candidate, Mazindol ER, for treatment of narcolepsy.
It has already received approval for the trial from the independent Institutional Review Board, and NLSP is attempting to speed approval by applying for a fast-track designation with the FDA.
As the NLSP CEO noted in a letter to shareholders, “A medicine that receives Fast Track Designation can be on the market within six months of the regulatory application.”
These things could be catalysts for a serious rocket-ride for the stock, but for our purposes, the current technical indicators are sufficient to suggest a big leg up in the near term.
Will that happen for sure? The future is never certain in the markets. There is always risk. But as I said, based on my analysis, this is looking like a pitch right over the plate.
You must do your own research, however.
I’m mortal, after all, and I want all my readers to get used to studying charts, examining fundamentals, and ultimately making up their own minds. Nothing is ever guaranteed in life or trading, so make wise decisions that consider your own personal risk profile.
This is an opportunity that might be gone before you know it, so take the time to learn more about NLSP right now and see if it makes sense for you.
From there, you’ll want to do an in-depth study of the stock’s chart. Again, the ticker is NLSP.
To Your Success,
*This investment involves substantial risk. Please see full disclosure below, and detailed discussion of risks and atypical results.
*PAID ADVERTISEMENT. Raging Bull has currently been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NLS Pharmaceutics AG from a period beginning on October 10 through October 11, 2023. Raging Bull has currently been paid twelve thousand five hundred dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NLS Pharmaceutics AG from a period beginning on September 1 through September 4, 2023. Raging Bull has previously been paid fifteen thousand dollars from Sica Media who was compensated by a third party not affiliated with the Company for advertising NLS Pharmaceutics AG from a period beginning on August 22 through August 24, 2023. To date, RagingBull has received forty two thousand five hundred dollars for marketing related to NLS Pharmaceutics AG. The third party, Company, or their affiliates may own and likely wish to liquidate shares of the Company at or near the time you receive this advertisement, which has the potential to hurt share prices. This advertisement and other marketing efforts, including alerts, may increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of NLS Pharmaceutics AG, increased trading volume, and possibly an increased share price of NLS Pharmaceutics AG’s securities, which may or may not be temporary and decrease once the marketing arrangement has ended. As a result of this advertisement and other marketing efforts, Raging Bull may receive advertising revenue from new advertisers and collect email addresses from readers that it may be able to monetize. As of the date of the issuance of this advertisement, the owners of Raging Bull do not hold a position in NLS Pharmaceutics AG, though they reserve the right to buy or sell shares in the covered company at any time following the dissemination of this communication.
FOR COMMERCIAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This advertisement is for commercial and informational purposes only. A portion of our business is engaged in the promotion, marketing, and advertising of companies including public companies. A portion of Raging Bull’s business model is to receive financial compensation to promote public companies, conduct investor relations advertising and marketing, and publicly disseminate information regarding public companies through our websites email, SMS, and push notifications among other methods of communication. This compensation is a major conflict of interest in our ability to provide unbiased reporting. Therefore, this communication should be viewed as a commercial advertisement only. Note, we periodically conduct interviews and issue stock alerts that we are not compensated for. These are purely for the purpose of company awareness, and to generate subscription revenues. We have not investigated the background of the hiring third party or parties. All material information contained in this advertisement is based on information generally available to the public, including information released to the public or filed by the Company with applicable regulators which public information is believed to be reliable and accurate. Nevertheless, Raging Bull cannot guarantee the accuracy or completeness of the information. This advertisement does not purport to be a complete analysis of any company’s financial position. This advertisement or any statements made in it is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. The statements made in this advertisement should NOT be relied upon for purposes of investing in the companies mentioned in this advertisement, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security mentioned in this advertisement or in any other security or strategy. It is strongly recommended that you consult a licensed or registered professional before making any investment decision.
SUBSTANTIAL RISK INVOLVED. Any individual who chooses to invest in any securities of the companies mentioned in this advertisement should do so with caution. Investing or transacting in any securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers of this advertisement bear responsibility for their own investment research and decisions and should use information from this advertisement only as a starting point for doing additional independent research in order to allow individuals to form their own opinion regarding investments. It is easy to lose money investing or trading, and we recommend always seeking individual advice from a licensed or registered professional and educating yourself as much as possible before considering any investments. Never invest in any stock featured in this advertisement, on our site or emails unless you can afford to lose your entire investment.
NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Raging Bull, or any of their owners, employees or independent contractors is not currently registered as a securities broker-dealer, broker, investment advisor (IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
USE OF FORWARD-LOOKING STATEMENTS. Our advertisements including this advertisement and related emails, reports and alerts may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors. We do not guarantee the timeliness, accuracy, or completeness of the information in this advertisement, related emails, reports or alerts or on our website or media webpage. This information is believed to be accurate and correct but has not been independently verified and is not guaranteed to be correct. Certain statements made in this advertisement may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and 21E of the Exchange Act of 1934. Forward-looking statements often include words such as “believes,” “anticipates,” “estimates,” “expects,” “projects,” “intends,” or other similar expressions of future performance or conduct. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made and are not statements of historical fact. They involve many risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. There is no guarantee that past performance will be indicative of future results. Raging Bull does not undertake an obligation to update forward-looking statements in light of new information or future events. Readers can and should review all public SEC filings made by the companies profiled in the Advertisements at https:// www .sec .gov/edgar/searchedgar/companysearch
TRADEMARKS. All trademarks used in this advertisement are the property of their respective trademark holders and no endorsement by such owners of the contents of the advertisement is made or implied.
WE MAY HOLD SECURITIES DISCUSSED. Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.